UFMG researchers have developed the Calixcoca vaccine, a potential breakthrough that could become the first immunization for treating cocaine and crack addiction.
Launched in 2015 by Professor Frederico Garcia of UFMG, the project has passed animal tests and is now preparing for phase 1 human trials, with submissions being finalized for Anvisa.
Researchers expect to begin human trials within the next two years and aim to have the vaccine fully developed and available within three to four years.
Innovative vaccine blocks cocaine’s path to the brain
Calixcoca’s approach is considered a major technological advance. It stimulates the immune system to produce antibodies that bind to cocaine in the blood, preventing it from crossing the blood-brain barrier. This prevents the drug from reaching the brain and triggering its psychoactive effects.
Garcia notes that, if proven effective, the vaccine could play an important role in helping patients reintegrate into society. By reducing the drug’s impact, it may help prevent relapse and give individuals in recovery more time to rebuild their lives.
The project has received strong institutional backing. In 2023, UFMG secured R$10 million in funding with support from the Minas Gerais government, Fapemig, and the Health Secretariat.This investment will support the project through its first phase of human trials.
Global award highlights breakthrough potential of vaccine
The Euro Innovation in Health Award recognized its global significance and provided €500,000 to support its development.
The project brings together a multidisciplinary team from medicine, pharmacy, and the exact sciences, including researchers from NAVeS. The Research Development Foundation (Fundep) also contributes by supporting the operational side of the project.
At present, there are no approved medications specifically for treating cocaine or crack addiction. Current treatments rely on behavioral therapy and symptom control, underscoring Calixcoca’s potential global impact.
Read the original article on: cff.org.br
Read more:China is putting AI-driven humanoid robots to use on its streets